Pharma Journalist -

ImmunityBio, Inc., a privately-held immunotherapy company, announced it has received authorization from the U.S. Food and Drug Administration (FDA) to begin a Phase I clinical trial of…
Read More...

Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has approved an expanded label for KEYTRUDA, Merck’s anti-PD-1…
Read More...

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, today announced the preclinical results for…
Read More...

Allogene Therapeutics, Inc. a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, and The University of Texas MD…
Read More...

Eli Lilly and Company announced a definitive agreement to acquire Disarm Therapeutics, a privately-held biotechnology company creating a new class of disease-modifying therapeutics for…
Read More...

Y-mAbs Therapeutics, Inc. a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the…
Read More...

Nestlé announced the successful completion of its acquisition of Aimmune Therapeutics, Inc. Joining Nestlé Health Science (NHSc) as a stand-alone business unit called Aimmune…
Read More...

Dyno Therapeutics, a biotech company applying artificial intelligence (AI) to gene therapy, announced a collaboration and license agreement with Roche to apply Dyno’s CapsidMap platform…
Read More...

Boehringer Ingelheim and Oxford BioTherapeutics Ltd. (OBT) announced they are building on their successful partnership and are establishing a new alliance to discover additional…
Read More...

Today, the U.S. Food and Drug Administration approved Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three monoclonal antibodies, as the first FDA-approved…
Read More...